PHARMA LITERATI

Source: http://www.hrpatelpharmacy.co.in/asojpharmvention/ICMPR-Details.php

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed. We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at  pharmaliterati@gmail.com Invention Application No Inventors Institute Development of potent poly-phyto capsules for dyslipidemia management using smart ideal antihyperlipdemic tree concept 2397/DEL/2014A 1) Dr. N. V. Satheesh Madhav 2) Kumud Upadhyaya 3) Asha Bisht Director, DIT-Faculty of Pharmacy Dehradun, Uttarakhand. Formulation process for a bionano gel loaded with chlorpromazine for brain targetting via trans nasal route 2373/DEL/2014 A 1) Dr. N. V

With the Ayurveda sector in the country heating up with new entrants such as Ramdev's Patanjali and HUL's Ayush, homegrown FMCG major Dabur has decided to strengthen its portfolio by inking a licence agreement with the Government of India to produce  two Ayurvedic drugs -one for management of diabetes and another for treatment of malaria  -to begin with. The company is preparing to bring these Ayurvedic medicines, which will be available in various formats, to the market within the next six months. While Ayush-64 , for malaria, can be used to both prevent the ailment and treat it, Ayush-82 can be used primarily to mana ge diabetes. “Around 50% of the count ry's population lives in mala ria-infested areas. This can prove to be a very cost effective solution,“ said Dr JLN Sastry head of healthcare research at Dabur India. “Both medicines are not over-the-counter drugs and ne ed to be prescribed by a doctor The ingredients used in the medicines are very simple

Allana College of Pharmacy, Pune and Women’s Forum, APTI jointly organize one day seminar on "Strategies for Empowerment of Women Associated with the Healthcare Profession". The  details  are as follows: Theme:         One day seminar on "Strategies for Empowerment of Women Associated with the Healthcare Profession".            Dates:                    8th March 2016. Organized by:          Allana College of Pharmacy, Pune .  Location:                Pune. Available at:             http://www.aptiindia.org/sites/default/files/women_forum_mar_8.pdf

The government of India has mandated National Institute for Pharmaceutical Education and Research (NIPER) Ahmedabad to initiate a National Centre for Medical Devices (NCMD) for development of skilled manpower in the medical device industry. This would involve collaborative inputs from the industry to help build innovation ecosystem and develop human resources for the industry along with a testing infrastructure at NIPER. This would also complement the first upcoming medical device testing lab of the country at Vadodara in Gujarat by the end of this year. The department of pharmaceuticals (DoP) for the last one year has actively engaged both the NIPERs and the pharma industry to build partnership in areas of education, research and development. Says Dr Kiran Kalia, director, NIPER, Ahmedabad, “As a part of the government initiative to develop an ecosystem for development of medical devices sector in the country, NIPER Ahmedabad has recently signed two MoUs with leading medi

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed. We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at  pharmaliterati@gmail.com Invention Application no Inventors Institute Urea complexes of chlorpyrifos, malathion, bifenthrin and cypermethrin for improving safe handling and other characteristics 201611002986A 1) Manish Dhall 2) A.K. Madan Faculty of Pharmaceutical Sciences, Pt. B. D. Sharma University of Health Sciences, Rohtak, Haryana. In-situ formation of lipidic nanoparticles 2307/DEL/2014A 1) Kaur, Indu Pal 2) Bhandari, Rohit 3) Singh, Mandeep 4

Battling monopoly and batting for the indigenous industry, YK Hamied scripts the drug-maker’s journey as challenges loom “ The best is yet to come .” That was the message from Cipla doyen Yusuf K Hamied in his townhall address to employees across the world, to mark the company’s 80th anniversary. Cipla has entered a dynamic phase in its growth, he said, outlining “six pillars” for the future — plants, products, partnerships, plans, passion and people. And this growth would also see the next generation of the Hamied family, with Samina Vaziralli (his niece) taking a hand to preserving the essence of the company. For those following the company’s journey, Cipla’s “best” may have been in 2001, whenit rocked the pharma world by offering the HIV/AIDS three-in-one drug Triomune at less than a dollar a day, breaking the stranglehold of Big Pharma in South Africa. The combined international price of these drugs then was $12,000 per patient per year. In fact, some health advo

Prominent pharma manufacturing companies are under the Drugs Control Association (DCA) radar for production of poor quality anticancer drugs. The DCA received complaints that the anticancer drug ‘ Vincristine’ imported from China is of poor quality and that some of important companies were using this as an Active Pharmaceutical Ingredients (API) in their units. Based on this information, checks were conducted on February 17 and 18 by 12 teams of regulators from DCA on prominent anti cancer manufacturing firms. The firms under the radar are Hetero Labs Ltd. at Kazipally and Jadcherla, Dr Reddy Labs Ltd , FTO at Bolarum, Dr Reddy Labs Ltd, CTO at Bolarum, Natco Pharma Ltd at Kothur and Nagarjuna Sagar, MSN Labs Ltd at Shameerpet, Shilpa Medicare at Jadcherla, Laurus Labs Ltd at Shameerpet, Accura Labs at Shameerpet, Celon Labs , ALEAP at Gajularamaram and Therdose Formulations , ALEAP at Gajularamaram. Five samples of the drug have been picked up and are being sent to t

USFDA is offering a web-based free course on biosimilars . The c ourse provides an understanding of biological products and biosimilar products and a description of FDA’s general approach to the development and approval of biosimilar products. The target audience for this course is healthcare professionals, including physicians, physician assistants, nurses, nurse practitioners, and pharmacists. The course comprises eight different modules : Module Title 1 Introduction 2 Biologics Price Competition and Innovation (BPCI) Act of 2009 3 What is a biological product? 4 Complexity of Biological Product Manufacturing 5 What is a similar Product? 6 Abbreviated Approval Pathway for Biosimilar Products 7 Standards for Approval 8 Conclusion Please visit: http://fdabiosimilars.e-paga.com/

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack. This large, international study was supported by the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS). The IRIS trial is the first study to provide evidence that a drug targeting cell metabolism may prevent secondary strokes and heart attacks even before diabetes develops. Insulin regulates metabolism and keeps blood sugar levels from getting too high, along with many other processes, in the body. Insulin resistance is a condition in which t

University of Findlay, Ohio has now collaborated with pharmacy colleges in India to widen the scope of pharmaceutical care in the country. At the Manipal University and St. Peter's Institute of Pharmaceutical Sciences, Warangal , University of Findlay’s College of Pharmacy has initiated global expert lectures and student exchange programmes where candidates get the required exposure about the advanced pharmacy practices in US. These include creation and maintenance of electronic prescription dispensing records and monitoring Narrow Therapeutic Index Drugs across patient population that can be replicated back home. The objective of this initiative is to develop a pharmacy service platform to open up job opportunities where pharmacists could chip in their expertise to ensure safe medication practices. A lot needs to be done in India in pharmacy care. To begin with, the accessibility of electronic medical records across healthcare providers will be a big game changer in India

The government wants to build an ecosystem to help pharma comapnies go up the value chain. Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers is expected to come out with a new bulk drug policy in less than a month with an objective to grow the Indian pharmaceuticals sector to a $200 billion industry by 2030. Under this policy, the government wants to build an ecosystem to help pharma companies to move up in the value chain and develop new molecules through innovations. “We are coming out with a new policy. This policy should been announced six months back. Now it will be unveiled in less than a month,” said Dr V K Subburaj, Secretary, Department of Pharmaceutical, Ministry of Chemicals and Fertilizers said. The industry which grew in the last 15 years has potential to be a $200 billion industry and can be the world’s largest if it scales up and moves up the value-chain. Until 1970 India was dependent on other countries for its pharmaceutical requ